Faculty

Back to Index
Louis VanderMolen, MD
Professor of Clinical Medicine
Medicine
NOR 1441 Eastlake Ave Health Sciences Campus Los Angeles

Overview

Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.

Awards

Phi Beta Kappa: Elected Member, 1977

Baylor College of Medicine: Chief Resident, Internal Medicine, 1983-1984

Orange County Medical Association: Physician of Excellence Award, 2006-2013

Publications

Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, McClure SE. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43. View in: PubMed

Kim B, Dillman RO, Chen P, Hafer R, Cox C, Barth N, Carroll RM, VanderMolen L, Nguyen M, Huang J, Minion A, Plunkett M, Mackintosh R. A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer. Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7. View in: PubMed

Dillman RO, Barth NM, VanderMolen LA, Fong WH, Mahdavi KK, McClure SE. Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7. View in: PubMed

Dillman RO, Barth NM, VanderMolen LA, Allen K, Beutel LD, Chico S. High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am J Clin Oncol. 2005 Jun; 28(3):281-8. View in: PubMed

Dillman R, Barth N, Vandermolen L, Mahdavi K, Beutel L, de Leon C, DePriest C, Nayak S. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80. View in: PubMed

Dillman RO, O'Connor AA, Simpson L, Barth NM, VanderMolen LA, Vanderplas P. Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5. View in: PubMed

VanderMolen LA, Sheehy PF, Dillman RO. Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest. 2002; 20(2):206-7. View in: PubMed

Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma. Cancer Biother Radiopharm. 2001 Feb; 16(1):47-54. View in: PubMed

Dillman RO, Wiemann MC, VanderMolen LA, Bury MJ, DePriest C, Church C. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm. 1997 Aug; 12(4):249-55. View in: PubMed

Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. J Clin Oncol. 1996 Aug; 14(8):2234-41. View in: PubMed

Dillman RO, Vandermolen LA, Barth NM, Bransford KJ. Malignant melanoma and pregnancy ten questions. West J Med. 1996 Feb; 164(2):156-61. View in: PubMed

Dillman RO, Barth NM, Mahdavi K, VanderMolen LA, Nayak SK, O'Connor A. The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center. Cancer Biother. 1995; 10(1):25-36. View in: PubMed

Vandermolen LA, Dillman RO. Primary lymphoma of the kidney: complete remission after systemic chemotherapy. J Natl Cancer Inst. 1993 Mar 17; 85(6):505-6. View in: PubMed

Sznol M, Clark JW, Smith JW, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst. 1992 Jun 17; 84(12):929-37. View in: PubMed

Powered bySC CTSI